The Guangxi disease control authority announced on August 22 that the Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control will conduct a Phase III clinical trial of an HPV vaccine for men in September. The trial will involve a domestically produced nine-valent vaccine and will follow up with 500 participants over six years. Many netizens are looking forward to men being able to receive the human papillomavirus (HPV) vaccine domestically.
Many netizens are looking forward to men being able to receive the human papillomavirus (HPV) vaccine domestically. On August 25, several clinical experts stated in interviews that from the perspective of herd immunity and disease prevention, it is essential for men to receive the HPV vaccine. After validating the indications, the domestic vaccination for men against HPV will inevitably be opened up.
It is reported that human papillomavirus (HPV) is one of the most common viruses worldwide, primarily transmitted through sexual contact, and is one of the most common pathogens of sexually transmitted diseases. HPV is also recognized as one of the four major carcinogenic pathogens in the world. Infection with HPV in men can lead to conditions such as genital warts, infertility, and various tumors. Existing studies indicate that HPV is related to almost all cases of genital warts, over 90% of cervical cancer, more than 60% of anal cancer, and around 70% of oropharyngeal cancer. Vaccination with the HPV vaccine (commonly referred to as the “cervical cancer vaccine” in the market) is the most effective way to prevent HPV infection, effectively preventing genital warts, cancers of the reproductive system, cervical cancer, oropharyngeal cancer, laryngeal cancer, among others, and can also reduce HPV infection and transmission among sexual partners.
This report is a synthesis from Chinanews.com, People’s Daily Health Client, Guangxi Disease Control.
(Source: Report compiled by Jimu News)
